Cancer vaccines: on the threshold of success
- 8 June 2008
- journal article
- review article
- Published by Informa Healthcare in Emerging Drugs
- Vol. 13 (2) , 295-308
- https://doi.org/10.1517/14728214.13.2.295
Abstract
Background: Cancer vaccines are a unique approach to cancer therapy. They exert an antitumor effect by engaging the host immune response, and have great potential for circumventing the intrinsic drug resistance that limits standard cancer management. Additional advantages of cancer vaccines are exquisite specificity, low toxicity, and the potential for a durable treatment effect due to immunologic memory. Objectives: This review aims to consider the promise of cancer vaccines, review the current state of cancer vaccine development, and suggest directions for future research. Methods: The scope of this review was defined peer-reviewed information found on Medline, and information found on the Internet about Phase III clinical trials that are ongoing and not yet published. Results/conclusions: Multiple Phase III clinical trials have demonstrated the promise and challenges posed by therapeutic vaccines, and defined the next steps in their clinical development. Determining the optimal integration of cancer vaccines with chemotherapy, radiation, surgery, and biologically targeted therapies, defining predictive biomarkers of immunologic and clinical response, and combining tumor vaccines with new drugs that effectively modulate the antitumor immune response, will ensure that cancer vaccines become part of standard cancer therapy and prevention.Keywords
This publication has 110 references indexed in Scilit:
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Inhibitory Effects of B Cells on Antitumor ImmunityCancer Research, 2006
- CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cellsJournal of Clinical Investigation, 2006
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006
- The global health burden of infection‐associated cancers in the year 2002International Journal of Cancer, 2006
- Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV MelanomaJournal of Clinical Oncology, 2005
- Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistanceOncogene, 2004
- How much longer will tumour cells fool the immune system?Immunology Today, 2000
- Dendritic Cells Generated From CD34+ Progenitor Cells With flt3 Ligand, c-Kit Ligand, GM-CSF, IL-4, and TNF-α Are Functional Antigen-Presenting Cells Resembling Mature Monocyte-Derived Dendritic CellsJournal of Immunotherapy, 2000